This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by Teelucksingh, S. Articles by Pinto Pereira, L. M Social Bookmarking                         What's this?

Metformin: an important tool for endocrinology in the West Indies. New tricks for an old drug

Department of Clinical Medical Sciences, The University of the West Indies, Eric Williams Medical Sciences Complex, Mt Hope. Trinidad, WI, pteelucksingh{at}gmail.com

Lexley M Pinto Pereira

Department of Paraclinical Sciences, The University of the West Indies, Eric Williams Medical Sciences Complex, Mt Hope. Trinidad, WI

Against the backdrop of an obesity pandemic, comes an increasing prevalence of metabolic (e.g. type 2 diabetes mellitus) and reproductive abnormalities (e.g. polycystic ovarian syndrome) mediated by the phenomenon of insulin resistance. Metformin is an inexpensive and widely available drug which partly through an insulin sensitising action has an antidiabetic action with unique cardioprotective effects and which has value in preventing progression of pre-diabetes to diabetes. Despite mounting favourable data its role in polycystic ovarian syndrome remains unsettled. The recent finding for its safety and efficacy in gestational diabetes, however, will no doubt lift concerns over its use in women in the reproductive age group. One immediate result would be its earlier and greater therapeutic application in under-resourced environments where cost and emotional barriers to insulin exist.

Key Words: gestational diabetes • insulin resistance syndrome • metformin • polycystic ovarian syndrome • pregnancy • reproductive age • West Indies

References

• Poon-King T., Henry MU, Rampersad F. Prevalence and natural history of diabetes in Trinidad. Lancet 1969;i:155-60.
• Miller GJ, Beckles GL, Maude GH et al. Ethnicity and other characteristics predictive of coronary heart disease in a developing community: principal results of the St James Survey, Trinidad. Int J Epidemiol 1989;18:808-17.[Abstract/Free Full Text]
• Fraser HS, Forrester T., Wilks R. The obesity epidemic of the Caribbean. West Indian Med J 1996;45:1-2.[Web of Science][Medline] [Order article via Infotrieve]
• Wilks R., Bennett F., Forrester T., McFarlane-Anderson N. Chronic diseases: the new epidemic. West Indian Med J 1998;47(suppl 4):40-4.[Web of Science][Medline] [Order article via Infotrieve]
• Verghese A. ‘Between Father and Son: Family Letters’ The New York Times January 16 2006, http://www.nytimes.com/books/00/01/16/reviews/000116.16verghet.html. Last accessed 21 July 2009.
• Wattley GH Heart disease in Trinidad. West Indian Med J 1960;9:189-93.[Medline] [Order article via Infotrieve]
• Barceló A. Cardiovascular diseases in Latin America and the Caribbean. Lancet 2006;368:625-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Forrester T., Wilks R., Bennett F. et al. Obesity in the Caribbean. Ciba Found Symp 1996;201:17-26[Medline] [Order article via Infotrieve]
• Bonora E. The metabolic syndrome and cardiovascular disease. Ann Med 2006;38:64-80.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Larrañaga I., Arteagoitia JM, Rodriguez JL et al. The Sentinel Practice Network of the Basque Country. Socio-economic inequalities in the prevalence of Type 2 diabetes, cardiovascular risk factors and chronic diabetic complications in the Basque Country, Spain. Diabet Med 2005;22:1047-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Wilder R., Majumdar S., Klarenbach S., Jacobs P. Socio-economic status and undiagnosed diabetes. Diabet Res Clin Pract 2005;70:26-30.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Bailey CJ, Campbell IW, Chan JCN et al. (eds). Metformin. The Gold Standard. Chichester: John Wiley & Sons Ltd, 2007;288.
• Swaby P., Wilson E., Swaby S. et al. Chronic diseases management in the Jamaican setting: HOPE worldwide Jamaica’s experience. P N G Med J 2001;44:171-5.[Medline] [Order article via Infotrieve]
• Mahabir D., Gulliford MC Changing patterns of primary care for diabetes in Trinidad and Tobago over 10 years. Diabet Med 2005;22:619-24.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854-65.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Marchesini G., Brizi M., Bianchi G. et al. Metformin in non-alcoholic steatohepatitis. Lancet 2001;358:893-4.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Ibáñez L., Ong K., Valls C. et al. Metformin treatment to prevent early puberty in girls with precocious pubarche. J Clin Endocrinol Metab 2006;91:2888-91.[Abstract/Free Full Text]
• Lord JM, Flight IHK, Norman RJ Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003;327:951-3.[Abstract/Free Full Text]
• Teelucksingh S., El-Youssef J., Sohan K., Ramsewak S. Prolonged inadvertent pravastatin use in pregnancy. Reprod Toxicol 2004;18:299-300.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Acosta I., Aponte Z., de-Jesús Z. et al. Prevalence of diabetes mellitus among pregnant women receiving health services at the Puerto Rico University Hospital, Puerto Rico, 1997-1998. P R Health Sci J 2001;201:65-70.
• Irving RR, Mills JL, Choo-Kang EG et al. The burden of gestational diabetes mellitus in Jamaican women with a family history of autosomal dominant type 2 diabetes. Rev Panam Salud Publica 2008;23:85-91.[Web of Science][Medline] [Order article via Infotrieve]
• Coetzee EJ Counterpoint: Oral hypoglyemic agents should be used to treat diabetic pregnant women. Diabetes Care 2007;30:2980-2.[Free Full Text]
• Rowan JA, Hague WM, Gao W. et al. MiG Trial Investigators. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med 2008;358:2003-15.[Abstract/Free Full Text]
• Glueck CJ, Goldenberg N., Pranikoff J. et al. Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. Hum Reprod 2004;19:1323-30.[Abstract/Free Full Text]
• Glueck CJ, Wang P. Metformin before and during pregnancy and lactation in polycystic ovary syndrome. Expert Opin Drug Saf 2007;6:191-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Lord JM, Flight IH, Norman RJ Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, d-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 2003;3:CD003053.[Medline] [Order article via Infotrieve]
• Teede HJ, Meyer C., Norman RJ Insulin-sensitisers in the treatment of polycystic ovary syndrome. Expert Opin Pharmacother 2005;6: 2419-27.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Tan S., Hahn S., Benson S. et al. Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. Eur J Endocrinol 2007;157:669-76.[Abstract/Free Full Text]
• Barbieri RL Clomiphene versus metformin for ovulation induction in polycystic ovary syndrome: the winner is J Clin Endocrinol Metab 2007;92:3399-401.[Free Full Text]
• Palomba S., Orio F. Jr, Falbo A. et al. Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:4068-74.[Abstract/Free Full Text]
• Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril 2008;89:505-22.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Polycystic Ovary Syndrome Writing Committee. American Association of Clinical Endocrinologists position statement on metabolic and cardiovascular consequences of polycystic ovary syndrome. American Association of Clinical Endocrinologists position statement on metabolic and cardiovascular consequences of polycystic ovary syndrome. Endocr Pract 2005;11:125-34.

The British Journal of Diabetes & Vascular Disease, Vol. 9, No. 5, 232-236 (2009)
DOI: 10.1177/1474651409346766


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by Teelucksingh, S. Articles by Pinto Pereira, L. M Social Bookmarking                         What's this?